Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

Urothelial carcinoma (UC) remains a significant health problem affecting an estimated 68,810 people in 2008 alone in the US. The majority of patients with metastatic disease develop disease recurrence, and long-term survival rates are poor. There is no standard of care for the treatment of patients with UC after the failure of cisplatin-based regimens in the first-line setting. Efforts to improve second-line treatment have led to the evaluation of single agents such as vinflunine and pemetrexed, and multidrug combinations with cytotoxic and targeted agents, including trastuzumab and bevacizumab. The authors reviewed the activity of several single agents and combination regimens in patients with UC. Emerging strategies for the measurement of response in clinical trials were also outlined.

Written by
Gallagher DJ, Milowsky MI, Bajorin DF.

Reference
Cancer. 2008 Jul 15. Epub ahead of print.
doi:10.1002/cncr.23692

PubMed Abstract
PMID:18629841

UroToday.com Bladder Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!